Responds to the National Assembly plenary session…Inner week Celltrion released the results of phase 2 clinical trials for antibody treatments
[서울=뉴스핌] Reporter Jeong Seung-won = The government announced that it will use the domestically developed anti-coronavirus infection (Corona 19) antibody treatment at the hospital and life treatment center dedicated to infectious diseases.
Chung Eun-kyung, head of the Centers for Disease Control and Prevention of the Centers for Disease Control and Prevention, answered inquiries from Democratic Party lawmaker Kim Seong-ju at the plenary session held at the National Assembly on the 8th.
 |
| Eun-kyung Jung, Head of Central Defense Countermeasure Headquarters [사진=질병관리청] |
On this day, the plenary session was held for’Emergency Questions on the quarantine status due to Corona 19, vaccine supply and demand status, and vaccination timing’, and’Emergency questions on the quarantine status due to Corona 19, vaccine supply and demand status and vaccination timing’. .
Corona 19 treatments currently being developed in Korea include antibody treatments and plasma treatments. The dual antibody treatment is being developed by Celltrion, and the results of phase 2 clinical trials are expected to be released on the 13th.
“Although it is in its infancy, we are doing our best to develop vaccines with a pan-governmental effort. The treatment of both antibody treatments and blood system drugs has completed phase 2 clinical trials and is about to undergo conditional approval.” I know that it will be released in Korea.”
“The characteristic of antibody therapy is that it is effective to prevent mild patients from becoming severely affected, and to use it within the first 7 days,” said Jung. “If the administration period is delayed, the diagnosis period is delayed, so the diagnosis period is delayed, and the hospital and life treatment for infectious diseases are “We will make it available in the center.”